If you’re a growth investor on the lookout for new options, then read on!
Listed below are two ASX growth that could be worth considering . Hereâs why analysts are tipping them as buys:
Aristocrat Leisure Limited (ASX: ALL)
The first ASX growth share to consider buying is Aristocrat Leisure. It is one of the worldâs leading gaming technology companies with a world class portfolio of poker machines and mobile games.  The latter business, known as Pixel United, is home to popular mobile games such as Cashman Casino, Gummy Drop, EverMerge, Mech Arena, and RAID.
Aristocrat also recently expanded into the real money gaming market with a deal with MGM. This has the potential to be a very lucrative business in the future and is partly why Goldman Sachs is positive on the company. It commented:
Real Money Gaming opportunity was discussed to grow to penetrate at least 70% of the regulated jurisdictions in north America in the medium term. ALL will be targeting to take a significant share of the US iGaming market in the medium term with ambitions to be a leading global online RMG platform in the long term.
Goldman has a buy rating and $42.80 price target on its shares.
ResMed Inc. (ASX: RMD)
Another ASX growth share that has been tipped as a buy is ResMed. It is a medical device company with a focus on sleep treatment solutions.
Morgans rates the company highly due to its strong position in the sleep treatment market and its huge potential in the out of hospital care market. The broker commented:
Nothing changes our medium/longer term view that the company remains well-placed as it builds a unique, patient-centric, connected-care digital platform that addresses the main pinch points across the healthcare value chain.
Morgans has an add rating and $37.24 price target on its shares.
The post Buy these ASX growth shares now: analysts appeared first on The Motley Fool Australia.
Trillion-dollar wealth shifts: first the Internet… to Smartphones… Now this…
Shark Tank billionaire Mark Cuban built his fortune on understanding technology. So when he says this one development is already taking over the business world, you may need to sit up and pay close attention.
He predicts it will soon become as essential to businesses as personal laptops and smartphones.
And it’s so revolutionary he’s even admitted “It’s the foundation of how I invest in stocks these days…”
So if you’re looking to get in front of a groundbreaking innovation… You’ll need to see this…
Learn more about our AI Boom report
*Returns as of March 1 2023
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- 5 ASX 200 shares that inflation can’t touch: expert
- Hereâs why experts rate these ASX 200 growth shares as buys
- Buy these excellent ASX 200 healthcare shares: Goldman Sachs
- Buy and hold these ASX 200 shares: brokers
- 2 ASX growth shares to buy: Goldman Sachs
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/vq6My5V
Stock Pick 